[Skip to Navigation]
Invited Commentary
March 30, 2021

Prevention of Severe Nonproliferative Diabetic Retinopathy Progression With More at Stake Than Visual Acuity

Author Affiliations
  • 1Department of Ophthalmology, University of Illinois at Chicago, Chicago
  • 2Associate Deputy Editor, JAMA Ophthalmology
JAMA Ophthalmol. 2021;139(7):714-716. doi:10.1001/jamaophthalmol.2021.0625

The results of DRCR Retina Network Protocol W study, published in this issue of JAMA Ophthalmology, show that aflibercept resulted in a more than 3-fold reduction in the incidence of center-involved diabetic macular edema (CI-DME) and a more than 2-fold reduction in the incidence of proliferative diabetic retinopathy (PDR) of eyes with moderate to severe nonproliferative diabetic retinopathy (NPDR), while showing no difference in visual acuity between aflibercept-treated and sham groups (with aflibercept administered in both groups if CI-DME or high-risk PDR developed) at 2 years.1 Therefore, should we offer prophylactic treatment with aflibercept to similar patients? Based on the Protocol W results, the natural history of NPDR progression to PDR and CI-DME, and the known risks and benefits of prophylactic aflibercept, my answer is yes. Patients with severe NPDR face the highest risk of progression to PDR, with or without DME. For this group, PDR develops in 14.6% of eyes at 1 year and 39.5% at 3 years.2 In eyes with very severe NPDR, the rates increase to 45% of eyes at 1 year and 64.9% at 3 years.2 Unfortunately, it is impossible to know specifically which of the eyes will progress and which will remain stable. Hence, preventive therapy entails unnecessary treatment of some eyes that would otherwise not progress. Thus, it is imperative to select the group of eyes with the highest risk for progression.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words